Monitoring Agency Report for Quarter II Ended September 30, 2025
Orchid Pharma submits Monitoring Agency Report for Q2 ended Sept 30, 2025, detailing utilization of QIP proceeds and revisions approved in AGM held on September 20, 2025.
The announcement is a standard update on the use of funds and doesn't present any significant strategic or financial shifts for the company.
The announcement is a routine compliance filing regarding the utilization of funds raised through QIP.
* Orchid Pharma Limited submitted the Monitoring Agency Report for Quarter II ended September 30, 2025. * The report was issued by CARE Ratings Limited regarding the utilization of proceeds raised through Qualified Institutions Placement (QIP). * The company revised the allocation of QIP proceeds among the objects specified in the offer document, pursuant to shareholders’ approval obtained through the AGM resolution dated September 20, 2025. * As of September 30, 2025, ₹73.02 crore has been utilized for investment in Orchid Bio Pharma Limited (OBPL) for setting up a manufacturing facility in Jammu, with ₹61.98 crore remaining unutilized. * ₹141 crore has been utilized for the repayment/prepayment of outstanding borrowings. * ₹0.36 crore has been utilized for funding capital expenditure requirements for setting up a new block at the API Facility in Alathur, Tamil Nadu. * ₹63.72 crore has been utilized for general corporate purposes. * The registration of remaining land parcel is expected to be completed upto December 2025 for setting up 7ACA project at Jammu. Construction activity of Major Building is in advance stage and Installation of equipment's already started.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.